Introduction: Turoctocog alfa is a recombinant factor VIII (FVIII) molecule, approved
| MATERIAL S AND ME THODS

| Trial design
This was a phase 3b, non-randomized, open-label, multicentre, multinational, single-arm, safety and efficacy extension trial (NCT00984126). Previously treated patients (PTPs) with severe haemophilia A (FVIII activity ≤1%) and no history of FVIII inhibitors were enrolled. Patients who had completed guardian 1 or guardian 3 or phase 1 pharmacokinetics trials and who chose to continue prophylaxis with turoctocog alfa in the guardian 2 extension trial were eligible. A 6-month on-demand sub-trial was subsequently added to ensure collection of sufficient on-demand regimen data.
Patients were included at 52 sites in 19 countries (Table S1 ). The trial was approved by all relevant independent ethics committees and institutional review boards. All participants provided written informed consent.
| Patients and treatment
Patients received prophylaxis or on-demand treatment with turoctocog alfa. Prophylaxis was administered as standard (20-50 IU/ kg once every second day or 20-60 IU/kg three times weekly) or as less-frequent prophylaxis (40-60 IU/kg twice weekly or once every third day). The dose and regimen were chosen by the investigator. For treatment of bleeds, the recommended dose level was 20-50 IU/kg.
Switching regimens and adjusting the dosing schedule was permitted.
Trial participation continued until turoctocog alfa was commercially available in the patient's country, until the predefined end of trial date or at the latest until 30 June 2016.
| Trial endpoints and clinical assessments
The primary safety endpoint was frequency of FVIII inhibitor development (≥0.6 BU). The secondary safety endpoint was frequency of adverse events (AEs) and of serious AEs (SAEs). 
| Statistical methods
No formal testing of statistical hypotheses was performed.
Haemostatic response was presented using a success/failure rate (bleeds with missing evaluations were excluded). Mean ABR was estimated using a Poisson model allowing for over-dispersion.
Frequency of inhibitor development was calculated as number of patients with inhibitors during the trial divided by number of patients in the trial with a 95% one-sided upper confidence limit.
| RE SULTS
A total of 214 patients were enrolled, 213 dosed with turoctocog alfa and 130 completed the main trial ( Figure S1 ). Patient demographic and baseline characteristics are shown in Table S2 .
Results: Overall, 213 patients were dosed with turoctocog alfa; 207 patients received prophylaxis; 19 received on-demand treatment. No FVIII inhibitors (≥0.6 BU) were reported. For all patients on prophylaxis, overall median ABR was 1.37 bleeds/y; success rate for treatment of bleeds was 90.2%; and 88.2% of bleeds were controlled with 1-2 injections of turoctocog alfa. For the on-demand regimen, overall median ABR was 30.44 bleeds/y; success rate for treatment of bleeds was 96.7%; and 94.9% of bleeds were controlled with 1-2 injections of turoctocog alfa.
Conclusion:
Extended use of turoctocog alfa is safe and effective for prevention and treatment of bleeding episodes in previously treated patients with haemophilia A across all ages.
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A total of 207 patients were treated prophylactically (27 on the less-frequent regimen) and 19 were treated on-demand. Trial sequences (ie, switching between treatment regimens) are detailed in Table S3 .
Accumulated number of patient-years for all 207 patients on prophylaxis was 730.8; for the 27 patients on less-frequent prophylaxis was 16.9; and for those treated on-demand was 16.3 (including in the on-demand sub-trial).
| Safety
No FVIII inhibitors were reported, with a 95% one-sided confidence upper limit of 1.4%. A total of 1260 AEs were reported in 183 (85.9%) patients (Table S4 ), corresponding to 1.7 AEs per patient-year of exposure. The most common AE (% of total patients) was nasopharyngitis (14.6%; Table S5 ).
Forty-seven SAEs occurred in 39 (18.3%) patients (Table S4) ; all except one event were judged "unlikely" related to turoctocog alfa treatment.
There was one fatal event in a 57-year-old patient on prophylaxis, which the investigator considered "unlikely" related to turoctocog alfa.
| Efficacy
| Prevention of bleeding episodes
In those on prophylaxis, 1782 bleeds were reported in 170/207 patients. Overall Poisson-estimated mean ABR among patients on prophylaxis was 2.44 bleeds/patient/y (95% confidence interval [CI]:
2.06-2.89 bleeds/patient/y); overall median ABR was 1.37 bleeds/y (range 0.00-17.82; Table S6 ). ABR by cause of bleed and location is shown in Figures S2 and S3 .
In those on less-frequent prophylaxis, 34 bleeds were reported in 13/27 patients. Overall Poisson-estimated mean ABR among patients on less-frequent prophylaxis was 2.01 bleeds/patient/y (95% CI: 1.21-3.33 bleeds/patient/y); overall median ABR was 0.00 bleeds/y (range 0.00-9.91; Table S7 ).
Mean per-patient consumption of turoctocog alfa for prophylaxis overall was 5094 IU/kg/y, with a mean dose level of 32.5 IU/ kg; corresponding figures for the less-frequent prophylaxis regimen were 5432 IU/kg/y and 48.2 IU/kg.
| Treatment of bleeding episodes
A total of 2173 bleeds were reported: 88.7% were classified as mild/ moderate and 11.2% as severe. In total, 1607 (74.0%) bleeds were stopped with one injection of turoctocog alfa and 336 (15.5%) with two injections. A mean (SD) of 1.6 (2.4) injections was required to stop the bleed, the median (range) time from first administration of turoctocog alfa until the bleed stopped was 7.7 (0.0-671.0) hours, and the mean consumption of turoctocog alfa from start to stop of the bleed was 58.9 IU/kg. Overall, the success rate for the treatment of bleeds was 91.4%.
Of the 1782 bleeds during prophylaxis, 1572 (88.2%) were stopped with 1-2 injections. A mean (SD) of 1.7 (2.6) injections was required to stop the bleed. Success rate for the treatment of bleeds was 90.2% (Table S8) 
| D ISCUSS I ON
The guardian 2 trial is one of the largest clinical trials to date conducted in patients with haemophilia A; 213 patients were exposed to turoctocog alfa, with 753 patient-years in the trial. The final results of guardian 2 are consistent with data from previous interim analyses. 7, 8 Turoctocog alfa was well tolerated, with no unexpected safety signals and no development of FVIII inhibitors. Thus, throughout the guardian 1, 2 and 3 trials, 238 PTPs with severe haemophilia A were exposed to turoctocog alfa for 856 patient-years and received a total of 136 471 injections without the occurrence of inhibitors.
9
The guardian 2 trial also evaluated a less-frequent dosing regimen (twice weekly or every third day) in selected patients, which demonstrated efficacy, with an overall median ABR of 0.00 (Poissonestimated mean ABR 2.01), and a treatment success rate of 94.1%.
These data suggest a subset of patients might be well managed with less-frequent dosing.
In conclusion, extended use of turoctocog alfa is safe and effective in the prevention and treatment of bleeding episodes across all age groups of PTPs with severe haemophilia A.
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